Moderna, bird flu

The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to ...
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...
Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...
Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...
Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...